Illustration: Sarah Grillo/Axios

We reported last week that, against the prevailing narrative that China has more or less already won the artificial intelligence race, some experts say there is still very much a contest: While China and its companies are spending a lot of money to dominate AI, we reported, they continue to be held back by intellectual inflexibility — they cannot or will not pivot as quickly as western researchers, and may be fated always to be behind.

Some FoW readers pushed back. Read on for their view

Their take is that China is either already in or on its way to the catbird seat when it comes to AI. "We do have sustainable differentiation, but China learns fast," Bart Riley, an advanced battery expert, told me.

I called around for more of this side of the debate.

  • Carnegie Mellon's Andrew Moore, also quoted in the previous post, told me that AI is moving along two tracks — research and development. And, if the aim ultimately is to be the greatest AI commercial gargantuan — to create the new Googles and Amazons, as discussed above — it is the latter category where focus is important.

Even if AI researchers make no further major advances, they have accomplished enough already "for hundreds or thousands of important applications of AI," Moore said. "There is plenty of new technology waiting for someone to get around and implement." These are in health care, education, self-driving and more, any of "which can have major economic impact." "What is blocking you is access to trained people. This is where China is in good shape." MooreMoore's big estimate: China is graduating about 50,000 new AI experts every year, about ten times the U.S. number.

  • Similarly, Hector Abruña, a professor and battery researcher at Cornell University, said the time is over when China's best students go to the U.S. to study and stay to live there. They still go to top U.S. universities for the cachet, but then many go back and work in leading labs at home. That has created "a dramatic turnaround" in terms of the quality of Chinese science, he told Axios.

The Chinese used to produce a lot of papers and patents that were notable mostly for their sheer quantity, Abruña said. "Not any more," he said. "They are publishing at the very best places, with very high quality work." And a new crop of Chinese researchers "straddles both cultures," he said. "That makes them dangerous. They are really pushing the envelope.

  • In a report today, the United Nations said that China has moved ahead of Japan as the second-biggest source of applications for international patents, Reuters reports.

Go deeper

Felix Salmon, author of Capital
14 mins ago - Economy & Business

How equity became more attractive than debt

Illustration: Annelise Capossela/Axios

The prime example of something highly improbable that became conventional wisdom: The idea that both interest rates and inflation will remain near zero for well over a decade.

Why it matters: As Axios' Dan Primack writes, private equity firms (the polite rebranding of "leveraged buyouts") have historically bought companies and loaded them up with debt.

Felix Salmon, author of Capital
17 mins ago - World

When society faces the unprecedented

Illustration: Aïda Amer/Axios

Our febrile world is not normal.

The big picture: The precautions that we're taking against the spread of COVD-19; the way in which the president of the U.S. delights in violating political norms; the fires, hurricanes and other signs that catastrophic global warming has arrived; the virulent spread of the QAnon conspiracy theory — all of these things, and many more, represent a stunning break with the world as we knew it.

Updated 3 hours ago - Politics & Policy

Coronavirus dashboard

Illustration: Eniola Odetunde/Axios

  1. Global: Total confirmed cases as of 11 a.m. ET: 34,026,003 — Total deaths: 1,015,107 — Total recoveries: 23,680,268Map.
  2. U.S.: Total confirmed cases as of 11 a.m. ET: 7,237,043 — Total deaths: 207,008 — Total recoveries: 2,840,688 — Total tests: 103,939,667Map.
  3. Health: New poll shows alarming coronavirus vaccine skepticism — New research centers will study "long-haul" COVID — Coronavirus infections rise in 25 states.
  4. Business: Remdesivir is good business for Gilead.
  5. Transportation: The politics of pandemic driving.
  6. 🎧Podcast: The looming second wave of airline layoffs.